Evaluación neuropsicológica en 129 pacientes chilenos con esclerosis múltiple recurrente remitente previo a inicio de fármacos inmunomoduladores

Nogales-Gaete, Jorge; Aracena, Rodrigo; Díaz, Vannia; Zitko, Pedro; Eloiza, Claudio; Cepeda-Zumaeta, Sergio; Agurto, Paula; González, Carola

doi:10.4067/s0034-98872012001100009

Cited by 8 publications

(3 citation statements)

References 28 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using the aforementioned criterion for defining abnormality showed that 35.5% of the patients had impairment. Similar figures were found by Nogales-Gaete et al 39 with a sample of Chilean patients with RRMS, but the finding here differs from other studies conducted in Oslo (Norway) and the UK and from another study in Spanish speaking patients in Argentina, 40 where the prevalence of cognitive impairment was >45%.…”

Section: Discussionsupporting

confidence: 82%

Cognitive status in patients with multiple sclerosis in Lanzarote

Pérez-Martín

Río

González-Platas

et al. 2016

NDT

View full text Add to dashboard Cite

ObjectivesCognitive impairment is a common feature in multiple sclerosis affecting ~43%–72% of patients, which involves cognitive functions such as memory, processing speed, attention, and executive function. The aim of this study was to describe the extent and pattern of the involvement of cognitive impairment and psychological status in all patients with multiple sclerosis on a small Spanish island.Patients and methodsIn all, 70 patients and 56 healthy controls were included in the study between February 2013 and May 2013. All participants were assessed using the Brief Repeatable Battery of Neuropsychological Test. The patients also completed instruments to evaluate the presence of fatigue, perceived cognitive dysfunction, and symptoms of anxiety and depression. All procedures were performed in a single session.ResultsCognitive impairment, defined as a score <1.5 standard deviation on two subtests of the battery, was present in 35% of the participants. The most frequently affected domain was working memory, followed by verbal memory and processing speed. Disease duration showed a moderate correlation with visuospatial memory and processing speed. The Expanded Disability Status Scale score correlated with verbal and processing speed. Verbal memory was correlated with depression symptoms and fatigue.ConclusionCognitive impairment was present in 35% of the study population. The most affected domains were working memory and verbal memory. Working memory and verbal fluency deficit are independent factors of disease evolution. Cognitive decline is related to clinical variables and psychological measures such as fatigue or depression but not to anxiety.

show abstract

Section: Discussionsupporting

confidence: 82%

Cognitive status in patients with multiple sclerosis in Lanzarote

Pérez-Martín

Río

González-Platas

et al. 2016

NDT

View full text Add to dashboard Cite

show abstract

“…Multiple sclerosis is a chronic disease, therefore long-term therapy constitutes the basis which apart from maintaining the patient's well-being should protect the patient from the disease relapses. Immunomodulating treatment uses interferon β-1-a and β-1-b, mitoxantrone, glatiramer acetate, natalizumab and fingolimod [ 12 – 14 ]. The choice of appropriate medication depends on the form and the kind of individual MS symptoms.…”

Section: Introductionmentioning

confidence: 99%

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study

Rudnicka

Czerwiec

Grywalska

et al. 2015

cejoi

View full text Add to dashboard Cite

BackgroundFingolimod is a drug administered orally to adult patients treated for relapsing remitting course of multiple sclerosis (MS). Mode of action of fingolimod is based on intense S1P1 receptor stimulation and “arresting” lymphocytes in lymphatic organs. Objective of the research was to assess changes in the frequencies of basic lymphocyte subsets in patients treated for multiple sclerosis with the use of fingolimod.Material and methodsStudy group comprised of 25 previously untreated adult patients with MS. Venous blood samples were collected from each patient before and one month, three months and six months after treatment initiation. Peripheral blood lymphocyte immunophenotype was assessed with a set of monoclonal antibodies bounded to appropriate fluorochromes and flow cytometer FACSC alibur. Statistical analysis of the results was conducted using Statistica 9.0 software.ResultsBefore fingolimod administration median of lymphocyte subsets percentage in each patient was in reference range. After 1 month of treatment we noticed significant changes in frequencies of following lymphocyte subsets: NK cells – 51.22% (p = 0.016), T CD4+ cells – 11.58% (p = 0.01), T CD4+:T CD8+ cells ratio – 0.61 (p = 0.005). After 3 and 6 months of treatment there was further increase of deviation from normal state.ConclusionsThe use of fingolimod is associated with profound changes in lymphocyte subsets distribution, which might bear a risk of the development of cellular immune deficiency symptoms.

show abstract

“…Realizamos: revisión de antecedentes demográficos, evaluación clínica neurológica, aplicación escala ampliada de discapacidad de Kurzke (EDSS), escala funcional compuesta, aplicación escala de intensidad de fatiga de Krupp, investigación de alteraciones cognitivas mediante batería neuropsicológica repetible breve de Rao (BNR-R) y manifestaciones depresivo-ansiosas mediante cuestionarios de Hamilton, Beck, o ambos. El análisis y versiones ocupadas en BNR-R y escalas de Hamilton o Beck están descritos en un trabajo previo nuestro 8 . Revisamos exámenes radiológicos registrando informes, observaciones complementarias y correlato con criterios de Barkhof-Tintoré 9 .…”

Section: Pacientes Y Métodounclassified

Esclerosis múltiple recurrente remitente en el sector público de salud de Chile: Descripción clínica de 314 pacientes

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

Evaluación neuropsicológica en 129 pacientes chilenos con esclerosis múltiple recurrente remitente previo a inicio de fármacos inmunomoduladores

Abstract: Background: The detection of cognitive changes (CC) and psychiatric disorders in relapsing remitting multiple sclerosis (MS-RR (Rev Med Chile 2012; 140: 1437-1444.

Cited by 8 publications

References 28 publications

Cognitive status in patients with multiple sclerosis in Lanzarote

Cognitive status in patients with multiple sclerosis in Lanzarote

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study

Esclerosis múltiple recurrente remitente en el sector público de salud de Chile: Descripción clínica de 314 pacientes

Contact Info

Product

Resources

About